139 related articles for article (PubMed ID: 21886519)
1. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.
Streeter SB; Schwartzberg L; Husain N; Johnsrud M
J Oncol Pract; 2011 May; 7(3 Suppl):46s-51s. PubMed ID: 21886519
[TBL] [Abstract][Full Text] [Related]
2. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.
Streeter SB; Schwartzberg L; Husain N; Johnsrud M
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP38-44. PubMed ID: 21711076
[TBL] [Abstract][Full Text] [Related]
3. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
4. Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines.
Wong WB; Donahue A; Thiesen J; Yeaw J
J Manag Care Spec Pharm; 2023 Mar; 29(3):324-334. PubMed ID: 36692908
[No Abstract] [Full Text] [Related]
5. Impact of pharmacy channel on adherence to oral oncolytics.
Stokes M; Reyes C; Xia Y; Alas V; Goertz HP; Boulanger L
BMC Health Serv Res; 2017 Jun; 17(1):414. PubMed ID: 28629454
[TBL] [Abstract][Full Text] [Related]
6. Association Between Cost-Sharing and Buprenorphine Prescription Abandonment.
Chua KP; Conti RM; Lagisetty P; Bohnert ASB; Nuliyalu U; Nguyen TD
J Gen Intern Med; 2024 Jun; ():. PubMed ID: 38888865
[TBL] [Abstract][Full Text] [Related]
7. Association Between Cost Sharing and Naloxone Prescription Dispensing.
Chua KP; Conti RM; Lagisetty P; Bohnert AS; He S; Nguyen TD
JAMA; 2024 Jun; ():. PubMed ID: 38869887
[TBL] [Abstract][Full Text] [Related]
8. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.
Doshi JA; Li P; Huo H; Pettit AR; Armstrong KA
J Clin Oncol; 2018 Feb; 36(5):476-482. PubMed ID: 29261440
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology of prescriptions abandoned at the pharmacy.
Shrank WH; Choudhry NK; Fischer MA; Avorn J; Powell M; Schneeweiss S; Liberman JN; Dollear T; Brennan TA; Brookhart MA
Ann Intern Med; 2010 Nov; 153(10):633-40. PubMed ID: 21079218
[TBL] [Abstract][Full Text] [Related]
10. Barriers to receipt of novel oral oncolytics: A single-institution quality improvement investigation.
Wang AA; Tapia C; Bhanji Y; Campbell C; Larsen D; Gross D; Ganatra S; Qodsi M; Tellez C; Jain S
J Oncol Pharm Pract; 2020 Mar; 26(2):279-285. PubMed ID: 30943846
[TBL] [Abstract][Full Text] [Related]
11. Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population.
Brixner D; Mittal M; Rubin DT; Mease P; Liu HH; Davis M; Ganguli A; Fendrick AM
Patient Prefer Adherence; 2019; 13():1545-1556. PubMed ID: 31571837
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir initial therapy abandonment and manufacturer coupons in a commercially insured population.
Karmarkar TD; Starner CI; Qiu Y; Tiberg K; Gleason PP
Am J Manag Care; 2016 May; 22(6 Spec No.):SP191-7. PubMed ID: 27266948
[TBL] [Abstract][Full Text] [Related]
13. Perceptions of Health-Care Workers of the Cost and Safety of Oral Oncolytic Agents for Patients: A Survey.
Tompkinson M; Fine K; Gruber D; Abraham I; McBride A
J Adv Pract Oncol; 2020; 11(4):354-365. PubMed ID: 33604096
[TBL] [Abstract][Full Text] [Related]
14. Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis.
Raborn ML; Pelletier EM; Smith DB; Reyes CM
J Oncol Pract; 2012 May; 8(3 Suppl):9s-15s. PubMed ID: 22942827
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a community pharmacy workflow process to identify and follow up with prescription abandonment.
Chancy P; Clifton CL; Branham AR; Hayes HH; Moose JS; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2019; 59(4S):S129-S135. PubMed ID: 31231004
[TBL] [Abstract][Full Text] [Related]
16. Impact of Online Prescription Management Systems on Biologic Treatment Initiation.
Hawkes JE; Mittal M; Davis M; Brixner D
Adv Ther; 2019 Aug; 36(8):2021-2033. PubMed ID: 31168763
[TBL] [Abstract][Full Text] [Related]
17. Factors Related to the Use of Topical vs. Oral NSAIDs for Sprains, Strains, and Contusions in a Senior Population: A Retrospective Analysis of Administrative Claims Data.
Sheer R; Schwab P; Essex MN; Cappelleri JC; Reiners A; Bobula J; Pasquale MK
Drugs Aging; 2018 Oct; 35(10):937-950. PubMed ID: 30203313
[TBL] [Abstract][Full Text] [Related]
18. Impact of multi-tiered pharmacy benefits on attitudes of plan members with chronic disease states.
Nair KV; Ganther JM; Valuck RJ; McCollum MM; Lewis SJ
J Manag Care Pharm; 2002; 8(6):477-91. PubMed ID: 14613381
[TBL] [Abstract][Full Text] [Related]
19. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
Clark BE; Siracuse MV; Garis RI
Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
[TBL] [Abstract][Full Text] [Related]
20. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use.
Shrank WH; Stedman M; Ettner SL; DeLapp D; Dirstine J; Brookhart MA; Fischer MA; Avorn J; Asch SM
J Gen Intern Med; 2007 Sep; 22(9):1298-304. PubMed ID: 17647066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
